03-0154-00

SMC^® Human cTnI High Sensitivity Immunoassay Kit

Used for ultrasensitive quantification of cTnI in human serum and plasma samples

• Synonym(e): Cardiac Muscle Troponin I immunoassay kit, Cardiac Troponin I immunoassay kit, cTnI Single Molecule Counting Kit, cTnI ultra-sensitive immunoassay
• NACRES: NA.84
• UNSPSC Code: 12161503
• Species reactivity: human
• Technique(s): single molecule counting: suitable
• Usage: kit sufficient for 96 wells
• Compatibility: for use with for use with FemtoQuest^™ and SMCxPRO^® instruments

Eigenschaften

• Produktname: SMC^® Human cTnI High Sensitivity Immunoassay Kit,
• description: Used for ultrasensitive quantification of cTnI in human serum and plasma samples
• product line: SMC^®
• usage: kit sufficient for 96 wells
• species reactivity: human
• technique(s): single molecule counting: suitable
• input: serum; plasma (K2 EDTA)
• UniProt accession no.: B6D427
• compatibility: for use with for use with FemtoQuest^™ and SMCxPRO^® instruments
• shipped in: wet ice
• storage temp.: 2-8°C

Beschreibung

General description

Cardiac Troponin I (cTnI) is a regulatory protein found in cardiac muscle tissue and plays a critical role in muscle contraction. It is released into the bloodstream following myocardial injury, making it a highly specific and sensitive biomarker for cardiac muscle damage. Elevated levels of cTnI are a key indicator of acute myocardial infarction (AMI) and are widely used in the diagnosis and risk stratification of patients with suspected acute coronary syndrome (ACS). Due to its high cardiac specificity and prolonged elevation post-injury, cTnI is considered a gold-standard biomarker for detecting even minor myocardial damage. High-sensitivity assays enable earlier detection of cardiac events, improving clinical decision-making and patient outcomes.

Features and Benefits

• Ultra-Low Detection Limits: Enables femtogram-level detection of cardiac troponin I, allowing early identification of myocardial injury.
• Expanded Dynamic Range: Accurately quantifies both baseline and elevated cTnI levels, supporting a wide range of research applications.
• Targeted Research Applications: Ideal for studies in cardiovascular disease, drug-induced cardiotoxicity, and cardiac safety assessment.
• Streamlined Lab Operations: Automation-compatible reagents reduce manual handling and improve workflow efficiency.
• Robust Performance: Delivers consistent, high-quality results for preclinical and translational research.

Packaging

96 well assay

Analysis Note

• Sensitivity: LLOQ 690 fg/mL* (SMCxPRO^® Instrument)
• Standard Curve Range: 170-600,000 fg/mL
• Intra-assay CV: <15%
• Inter-assay CV: <20%
• Linearity: Serum: 80% Plasma: 85%
• Recovery: Plasma: 119%

*Indicative LLOQ created from average of 14 independent in house runs, where >80% met same value defined with CV & Recovery +/- 20%. Refer to CoA for lot specific performance.

Cardiovascular

Other Notes

Although cTnI was detectable in non-human primate, mouse, rat, canine and equine samples, the assay has not been verified for these species.

Legal Information

FEMTOQUEST is a trademark of Merck KGaA, Darmstadt, Germany

SMC is a registered trademark of Singulex

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sicherheitshinweise

• pictograms: GHS06,GHS08
• signalword: Danger
• Lagerklasse: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• hcodes: H302 + H332,H311,H319,H360FD,H412,EUH430
• pcodes: P201 - P202 - P273 - P280 - P308 + P313 - P391 - P405 - P501
• Hazard Classifications: Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - ED ENV 1 - Eye Irrit. 2 - Repr. 1B